Cited by 142SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies

Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Open access
Marion, Olivier, Del Bello, Arnaud, Abravanel, Florence, Couat, Chloé, Faguer, Stanislas, Esposito, Laure, Hebral, Anne Laure, Izopet, Jacques +1 more·2021·Annals of Internal Medicine

Abstract

Background: Recipients of solid organ transplant (SOT) are a high-risk group for severe SARS-CoV-2 infection. The mortality rate of patients with SOT during the COVID-19 pandemic has been reported to be approximately 20% (1). The anti–SARS-CoV-2 vaccines represent a hope to protect this population against this life-threatening infection.Objective: To assess the humoral response to messenger RNA (mRNA)–based vaccination in recipients of SOT.Methods: All patients with heart, kidney, liver, or pancreas transplants from the Midi-Pyrénées region (southwest France) are followed in our department. When the vaccination campaign started (7 January 2021), these patients were invited via text message, e-mail, or transplant patients' associations to be vaccinated. Patients were asked to register via a dedicated telephone number or website. They were vaccinated consecutively according to their registration date. According to the recommendations of the Francophone Society of Transplantation, anti–SARS-CoV-2 spike protein antibodies were monitored before and after vaccination. We used the SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay test (Beijing Wantai Biological Pharmacy Enterprise) (80% of patients) or another validated anti–SARS-CoV-2 spike protein assay. According to French law (loi Jardé), anonymous retrospective studies do not require institutional review board approval.Findings: By 16 April 2021, 950 patients of the 2666 from our cohort had received at least 1 dose of an mRNA vaccine (BNT162b2 vaccine [Pfizer-BioNTech], n = 942; mRNA-1273 vaccine [Moderna], n = 8) and had anti–SARS-CoV-2 antibodies monitored. Fifty patients had vaccination without monitoring of antibodies, 80 patients are planned to be vaccinated within the next month, and 257 patients declined the vaccine. We had no feedback from the remaining 1329 patients.

Integrity signals

Registry

Crossref · 10.7326/m21-1341

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Participants with immunosuppression had consistently lower antibody responses, with neutralizing antibody titers five times lower than those without immunosuppression.

    “Similar to the findings in other reports,17-19 a significantly lower antibody response was found consistently through the observation period among participants with immunosuppression, who had neutralizing antibody titers that were lower by a factor of 5 than those among participants without immunosuppression.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Marion, O., Del Bello, A., Abravanel, F., Couat, C., Faguer, S., Esposito, L., Hebral, A. L., Izopet, J., & Kamar, N.
Affiliations
  • Université Toulouse III - Paul Sabatier (FR)
  • Toulouse Rangueil University Hospital and Paul Sabatier University, Toulouse, France
  • Hôpital Rangueil (FR)
  • Toulouse Rangueil University Hospital, Toulouse, France
Venue
Annals of Internal Medicine
Published
2021-09
Volume
174
Issue
9
Pages
1336-1338
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W3164162028
Cited by
142
References
5
Citations by year
2026: 2 · 2025: 6 · 2024: 12 · 2023: 22 · 2022: 63 · 2021: 37
FWCI
10.61
Type
journal article
Language
en
Open access
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 vaccines, mRNA vaccines, solid organ transplant recipients, vaccine safety, immunogenicity, immunosuppression
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Viral, Female, Humans, Male, Middle Aged, Immunocompromised Host, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review